Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study of VS-505 to Evaluate the Tolerability, Safety and Efficacy in End Stage Renal Disease Patients Undergoing Hemodialysis

NCT02469467 is registered in ClinicalTrials.gov with KDL Inc. as lead sponsor.

NCT NCT02469467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02469467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study of VS-505 to Evaluate the Tolerability, Safety and Efficacy in End Stage Renal Disease Patients Undergoing Hemodialysis
Lead sponsor
KDL Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2015
Completion date
December 31, 2016
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, hyperphosphatemia